Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Q BioMed Inc QBIO

Healthcare Biotechnology
Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated... see more

Recent & Breaking News (GREY:QBIO)

Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East

PR Newswire July 12, 2021

Q BioMed Inc. Discusses Progress of COVID-19 Therapeutic and $30 Million Potential Investment with The Stock Day Podcast

Newsfile June 23, 2021

Q BioMed Insider to Invest up to $30M in the Company

PR Newswire May 11, 2021

Q BioMed Updates Shareholders

PR Newswire April 27, 2021

Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs

PR Newswire March 2, 2021

Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US

PR Newswire February 1, 2021

Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer

PR Newswire January 27, 2021

Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan

PR Newswire January 26, 2021

Strontium89 Now Reimbursed in Hospital and Outpatient Settings for Metastatic Bone Pain Treatment

PR Newswire January 7, 2021

Q BioMed Updates Shareholders at Year End

PR Newswire December 29, 2020

Q BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 Consortium

Canada NewsWire December 21, 2020

Q BioMed's Uttroside-B Receives U.S. Patent in Treatment of Liver Cancer

PR Newswire November 16, 2020

Q BioMed Inc. Discusses Revenue Potential of International Commercialization and Expansion of Strontium89 with The Stock Day Podcast

Newsfile October 14, 2020

Q BioMed, Inc. CEO Discusses Recently Announced International Market Authorizations and Expansion in to South and Central America and Asia for Q BioMed's Strontium89, its FDA Approved Drug for the Non-Opioid Treatment of Metastatic Cancer in the Bone

GlobeNewswire September 22, 2020

Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and Europe

PR Newswire September 15, 2020

Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program

PR Newswire August 26, 2020

Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World

PR Newswire August 11, 2020

Q Biomed to Scale up Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer, in Preparation for IND Filing

PR Newswire July 22, 2020

Q BioMed, Inc. CEO Discusses Recently Announced Global Distribution Partnership with Caligor Coghlan Pharma Services in Audio Interview with SmallCapVoice.com

GlobeNewswire July 9, 2020

Q BioMed Announces Global Distribution Partnership With Caligor Coghlan Pharma Services for its Non-Opioid Cancer Palliation Drug

PR Newswire July 8, 2020